25 May 2013
Keywords: elan, axogen, ph, iii, neurobloc, data, corp
Article | 23 April 1998
Elan Corp and Axogen Ltd have reported successful Phase III trialsof Neurobloc (botulinum toxin type B) in cervical dystonia. The
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com